“…One advantage of phage therapy is the large application without disruptions to the gut microbiota . A vast abundance of the phages in nature also ensures a nearly endless pipeline enabling application as “cocktails”, thereby reducing the chances of resistance developing to an individual treatment. − Some recent clinical studies including treatment of Staphylococcus aureus in prosthesis infections, Mycobacterium abscessus , Burkholderia dolosa , and Achromobacter xylosoxidans in lung transplants, − Acinetobacter baumannii in pneumonia, and Klebsiella pneumoniae in fracture-related infections . Phase II clinical trials have also been undertaken, including the European Phage Therapy Unit (PTU) between 2008 and 2010 reporting full recovery or clinical improvement in 40% of patients (157 total), treatment of leg ulcer pathogens using Intralytix phage cocktail WPP-201 (targeting E. coli , S. aureus , and Pseudomonas aeruginosa ), which reported no side effects, and some currently ongoing clinical trials .…”